SOFINNOVA-PARTNERS
19.10.2021 07:02:07 CEST | Business Wire | Press release
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the close of its latest early-stage healthcare venture capital fund, Sofinnova Capital X, oversubscribed at €472 ($548) million. This brings the total amount the VC has raised to €1 billion in the last 12 months across its multi-fund platform, and the total AUM to over €2.5 billion. Capital X, the 10th iteration of Sofinnova Partners’ flagship fund, is the largest healthcare fund dedicated to early-stage investments and company creation in Europe.
Sofinnova Capital X will invest in the most promising biopharmaceutical and medical device start-ups that address pressing unmet clinical needs and aim to transform patients’ lives. In keeping with the current strategy, the team will source and create value across a portfolio of groundbreaking innovations in healthcare, supporting entrepreneurs globally in the creation and growth of their companies.
Capital X was successfully raised with institutional investors including pension funds, insurance companies, foundations, endowments, corporate investors, and prominent family offices from across Europe, Asia, and North America. The Fund welcomed back existing investors and attracted new blue chip limited partners, reflecting sustained confidence in the firm’s capacity to generate strong financial returns.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners , said: “The close of Capital X, significantly oversubscribed and raised in record time, comes at a pivotal moment as the importance of healthcare innovation has become exceedingly clear to all. The fact we have been able to raise €1 billion across our platform over the past 12 months is a tribute to our investors and their conviction in our ability to bolster our leading position in Europe.”
Henrijette Richter, Managing Partner of Sofinnova Partners , said: “We are thrilled to have raised the largest fund dedicated to early-stage healthcare investments in Europe. This is an important milestone for Sofinnova Partners. Capital X will allow us to leverage over 30 years of cumulative experience perfecting this strategy. We now have more capital than ever to support leading entrepreneurs as they launch new companies to develop groundbreaking therapies that have the potential to change peoples’ lives.”
Clifford Chance acted as legal counsel and Triago as placement agent.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018006050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gaétane Baudry Appointed Senior Vice President/Global General Manager, Bobbi Brown8.10.2026 14:00:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Gaétane Baudry as Senior Vice President/Global General Manager, Bobbi Brown, effective October 8, 2026. Based in New York, she will report to Lisa Sequino, Global President, Makeup Brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008525584/en/ Gaétane Baudry In this role, Gaétane will lead Bobbi Brown’s global strategy and continued evolution, strengthening the brand’s distinctive equity, advancing innovation and creativity, and deepening consumer engagement around the world. “Gaétane is an inspiring and highly collaborative leader who brings experience, energy and a strong focus on execution,” said Lisa Sequino, Global President, Makeup Brands. “Her global brand-building record, strong commercial leadership and passion for creating meaningful consumer experiences will be invaluable as Bobbi Brown builds on its unique brand equity focused
Adtran launches Mosaic One Agents to help teams easily scale operations8.10.2026 14:00:00 CEST | Press release
News summary: Rapidly growing networks, operations and customer demands call for new ways to scale expertise Mosaic One Agents provides role-specific AI agent teams for network management, customer care and business operations Agent teams use data from Adtran and third-party hardware to investigate problems in parallel while organizations retain control Adtran today launched Mosaic One Agents, a suite of AI agents designed to help organizations scale expertise across network management, customer care and business operations. Built on Mosaic One Fabric, it gives role-based agent teams access to data from Adtran and third-party networks, enabling them to investigate issues, coordinate work across teams and drive issues through to resolution. By handling time-consuming investigation, coordination and process tasks, Mosaic One Agents helps people resolve issues faster, extend their expertise across more workflows and retain control of critical network and business actions. “When something
The LYCRA Company to Spotlight Renewable LYCRA® Fiber and Textile-to-Textile Circularity at Textile Exchange Conference 20268.10.2026 14:00:00 CEST | Press release
The LYCRA Company, a global leader in fiber and technology solutions for the apparel and personal care industries, will showcase Renewable LYCRA® fiber and its work to advance textile-to-textile recycling at Textile Exchange Conference 2026. The conference takes place October 12–16, at the Vancouver Convention Centre in Vancouver, Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008178765/en/ At the Textile Exchange Conference 2026, The LYCRA Company will showcase Renewable LYCRA® fiber and its progress in advancing textile-to-textile recycling. This year's theme, "The Implementation Era," focuses on scaling what works across businesses, supply systems, and landscapes. At the conference, The LYCRA Company will highlight its work with partners across the value chain, helping to shape the future for textiles through renewable fiber solutions, circular innovation, and strategic industry partnerships. “Bringing more rec
ARIS Strengthens Global Leadership Team with Three Senior Appointments to Accelerate 2027 Growth8.10.2026 14:00:00 CEST | Press release
Process Context Platform for Enterprise AI adds new Chief Product Officer, Global Head of Strategy & Transformation and Americas sales lead to help capitalize on growing enterprise demand for trusted, scalable AI ARIS, the global leader in Process Context for Enterprise AI, today announced three new senior appointments as it builds momentum toward 2027 and accelerates its strategy to help organizations put AI to work at scale. Maxime Hambersin joins as Chief Product Officer, Dr. Benjamin Krusche as Global Head of Strategy & Transformation, and Mark Jacobs as President and Go-to-Market Lead, Americas. The appointments further strengthen the leadership team built around CEO Guillaume Bacuvier and support the company's next phase of global growth. They come as ARIS advances its positioning around Process Context – giving AI agents the business understanding they need to operate effectively – while accelerating a product roadmap designed to help enterprises identify, deploy and scale AI ag
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer8.10.2026 13:30:00 CEST | Press release
Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combinationArmenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of quality, nonclinical, clinical and pharmacovigilance dataApprovals supported by clinical evidence published in peer-reviewed journals and presented at major oncology congresses, including two-year Phase 1b survival findings and randomized Phase 2 data in MSS metastatic colorectal cancer without active liver metastasesAgenus will evaluate the potential for approvals in other Eurasian Economic Union countries that support this regulatory path Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatell
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom